TB-500 (Thymosin Beta-4) 10mg Review

TB-500 is the research designation for a synthetic, acetylated peptide fragment corresponding to the full 43-amino acid sequence of Thymosin Beta-4 (TB4), a protein first isolated from bovine thymus tissue in the early 1980s. Over the past two decades it has attracted substantial preclinical interest because of its documented roles in actin sequestration, directed cell migration, angiogenesis, and tissue repair across multiple organ systems. 1

This review covers the Apollo Peptide Sciences 10 mg vial formulation. Every claim about mechanism, pharmacokinetics, or efficacy is anchored to peer-reviewed, PubMed-indexed literature. Where evidence is thin or contested, that is stated plainly. Researchers who are new to peptide handling should also consult our reconstitution guide and dosage calculation guide before proceeding.

Editor's Verdict

TB-500 occupies a well-defined mechanistic niche. Its core activity, sequestering globular (G-)actin and promoting actin polymerization dynamics, underlies a cascade of downstream effects including keratinocyte migration, endothelial tube formation, and cardiomyocyte survival signaling. 2 That mechanistic clarity is a significant strength compared with many peptides whose proposed targets remain speculative.

The compound is not without complexity. Some published cardiac regeneration findings have not replicated cleanly across independent laboratories, and the relationship between dose, route of administration, and tissue-specific effect requires more rigorous characterization before confident conclusions can be drawn. 3 Researchers entering this field should treat the existing animal literature as a starting framework rather than a definitive map.

Specifications

The 10 mg vial size is practical for multi-experiment rodent protocols. At a typical in-vivo research concentration of 5 mg/kg in a 25 g mouse, a single vial provides approximately 80 individual doses, though reconstituted solution stability limits the practical window to two to three weeks even under cold storage. Researchers planning extended protocols should consider aliquoting immediately after reconstitution and storing at -80°C. See the reconstitution guide for detailed technique.

What It Is: Chemistry, Origin, and Sequence Detail

Historical Discovery and Nomenclature

Thymosin Beta-4 was first isolated and sequenced by Low and colleagues at the National Cancer Institute in 1981, originally identified as a 43-amino acid peptide from calf thymus with immunomodulatory properties. 4 The "thymosin" family designation is somewhat misleading given later research established that TB4 is expressed ubiquitously across tissue types rather than being thymus-specific, with high concentrations found in platelets, macrophages, cardiac muscle, and wound fluid. 5

The research designation "TB-500" gained traction primarily in the veterinary performance literature before being adopted by the broader peptide research community. It consistently refers to the synthetic, acetylated 43-mer rather than any shorter fragment. The related compound Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), a four-amino acid sequence corresponding to the N-terminal tetrapeptide of TB4, is a distinct research compound with its own pharmacology and should not be confused with TB-500 despite being released by endogenous proteolysis of TB4 in vivo. 6

Primary Sequence and Critical Structural Features

The full 43-amino acid sequence begins with the acetylated N-terminus (Ac-Ser¹) and ends at Glu⁴³. The N-terminal acetylation is not cosmetic. Unacetylated TB4 analogs show substantially reduced actin-binding affinity and diminished biological activity in cell migration assays, establishing the acetyl group as functionally essential rather than merely a stability modification. 7

The central actin-binding domain spans residues 17-23 and contains the LKKTETQ motif (in the context of the full TB4 numbering). Site-directed mutagenesis experiments by Hannappel and colleagues confirmed that disruption of this motif abolishes G-actin sequestering activity while leaving the N-terminal Ac-SDKP region intact. 8 This modular architecture means TB-500's biological effects are, in principle, decomposable into at least two functional zones: the N-terminal anti-inflammatory/hematopoietic zone and the central actin-regulatory zone.

Circular dichroism (CD) spectroscopy studies demonstrate that TB-500 does not adopt a stable secondary structure in aqueous solution at physiological ionic strength. The peptide exists predominantly as a random coil, a configuration that facilitates interaction with the barbed end of G-actin through an extended surface contact rather than a lock-and-key binding event. 7 This structural flexibility also makes TB-500 particularly sensitive to temperature-mediated aggregation in concentrated solutions, an important consideration for reconstitution protocol design.

Synthesis and Manufacturing Considerations

Commercial TB-500 for research applications is synthesized almost exclusively by solid-phase peptide synthesis (SPPS) using Fmoc chemistry. The 43-residue length and the requirement for N-terminal acetylation make this a moderately complex synthesis with several potential failure points, particularly at the lysine-rich segment around residues 14-20 where incomplete coupling or deletion sequences are common. 9 Researchers should request mass spectrometry confirmation alongside HPLC purity data; a single-peak HPLC chromatogram can conceal a deletion sequence of identical charge state that would pass undetected without MS verification.

Mechanism of Action

Actin Sequestration and Cytoskeletal Dynamics

The best-characterized molecular function of TB-500 is its role as a G-actin sequestering protein. Under physiological conditions, approximately 80-90% of intracellular TB4 is bound to monomeric G-actin in a 1:1 complex, effectively functioning as an actin buffer that controls the pool of free G-actin available for filament (F-actin) polymerization. 2 When cells receive migratory signals, localized release of TB4 from this complex allows rapid, directed actin polymerization at the leading edge lamellipodium, providing the cytoskeletal push required for cell movement.

The binding affinity of TB-500 for G-actin has been measured at approximately Kd = 0.5-2.0 microM in multiple biophysical studies using fluorescence polarization and isothermal titration calorimetry. 7 This moderate affinity is physiologically appropriate: tight enough to maintain a significant free G-actin buffer, loose enough to allow rapid exchange when local conditions shift. Importantly, TB4/TB-500 does not simply cap actin filaments; it competes with profilin for G-actin binding, creating a dynamic regulatory interplay between two families of actin-binding proteins that collectively set the polymerization rate. 2

Integrin Receptor Engagement and Cell Migration

Beyond cytoskeletal regulation, TB-500 promotes cell migration through direct engagement with integrin receptors on the cell surface. Studies using surface plasmon resonance and competitive binding assays have identified integrin alpha-v beta-3 (alphavbeta3) and integrin alpha-5 beta-1 (alpha5beta1) as TB4 binding partners, with these interactions mediating downstream activation of focal adhesion kinase (FAK) and the PI3K-Akt signaling pathway. 10

FAK activation by TB-500 promotes the formation of new focal adhesions at the leading cell edge, while simultaneously triggering Akt-mediated survival signaling that reduces apoptosis in cells at wound margins. 10 This dual pro-migratory and pro-survival combination is mechanistically important because tissue repair requires not just cell movement into a wound zone but also survival of cells exposed to the harsh inflammatory microenvironment of a fresh injury. The net result in excisional wound models is accelerated re-epithelialization and granulation tissue formation, consistent with findings from multiple in-vivo studies reviewed in the research section below.

Angiogenic Signaling

TB-500 upregulates vascular endothelial growth factor (VEGF) expression in multiple cell types through a mechanism that appears to involve hypoxia-inducible factor 1-alpha (HIF-1alpha) stabilization and direct transcriptional effects at the VEGF promoter. 11 In endothelial cells, exogenous TB-500 treatment stimulates tube formation in Matrigel assays at concentrations as low as 100 nM, suggesting high potency for angiogenic promotion relative to its actin-binding affinity.

The angiogenic activity of TB-500 has been replicated in multiple in-vivo models including corneal micropocket assays, full-thickness skin wound models, and myocardial infarction models in rodents. 11 This neovascularization is generally regarded as beneficial in the context of ischemic tissue repair but represents a potential concern in the presence of pre-existing malignancy, where tumor vascularity is already a therapeutic target. This dual-edged nature of angiogenic promotion is addressed in the safety section.

Anti-Inflammatory Signaling

The Ac-SDKP tetrapeptide released from the N-terminus of TB4 by prolyl oligopeptidase (POP) exerts anti-inflammatory effects through inhibition of NF-kappaB nuclear translocation and downregulation of TNF-alpha and IL-1beta secretion in activated macrophages. 6 While TB-500 itself carries this tetrapeptide sequence at its N-terminus, the extent to which intact TB-500 generates Ac-SDKP in experimental systems depends on local POP enzyme activity and may vary substantially across tissue and cell types.

Tissue Distribution and Expression Context

Endogenous TB4 expression is highest in tissues with high cell turnover or frequent injury exposure, including skin, intestinal epithelium, cornea, and bone marrow. 5 Exogenously administered TB-500 accumulates preferentially at sites of active inflammation and injury in rodent models, an observation attributed to elevated integrin expression and altered proteoglycan composition in the extracellular matrix of injured tissue. 12 This preferential distribution to injury sites is relevant to the concept of "targeted" delivery, though the mechanistic basis for this homing remains incompletely characterized.

What the Research Says

Study 1: Wound Healing in Full-Thickness Excisional Models (Philp et al., 2004)

Philp and colleagues published one of the foundational in-vivo wound healing studies for TB4 in the Annals of the New York Academy of Sciences in 2004. The research team used a full-thickness excisional wound model in aged (18-month-old) mice, a population known to exhibit significantly impaired healing compared with young animals. 13

The design compared topical application of TB4 peptide (0.5 microg per wound per application, applied twice weekly) against vehicle control over a 21-day observation period. Primary endpoints included wound area reduction measured by digital planimetry, histological assessment of re-epithelialization depth, collagen deposition by Masson's trichrome staining, and immunohistochemical quantification of keratinocyte migration markers.

Results showed statistically significant acceleration of wound closure in TB4-treated animals relative to controls (p < 0.01 at day 14), with treated wounds achieving 80% closure by day 14 compared with approximately 55% in vehicle controls. Histological analysis demonstrated increased keratinocyte migration distance and earlier formation of organized granulation tissue in treated wounds. The authors attributed these effects primarily to TB4's role in actin reorganization in migrating keratinocytes, consistent with the mechanistic framework described above.

Limitations of this study include the use of topical rather than systemic delivery, which makes dose quantification and systemic pharmacokinetic interpretation difficult. The aged mouse model, while clinically relevant for wound healing research, may not represent healing dynamics in young adult animals used in subsequent studies. Additionally, the low topical dose (0.5 microg) does not translate to a systemic mg/kg equivalent, limiting direct comparison with later systemic injection studies.

Study 2: Cardiac Repair After Myocardial Infarction (Bao et al., 2010)

Bao and colleagues published a prominent cardiac repair study in Cardiovascular Research in 2010, examining the effect of TB4 treatment on left ventricular remodeling following experimental myocardial infarction (MI) in mice. 1 The experimental model involved permanent ligation of the left anterior descending (LAD) coronary artery followed by systemic intraperitoneal (IP) injection of TB4 at 150 microg per mouse (approximately 6 mg/kg for a 25 g mouse) on days 1, 7, and 14 post-ligation.

Primary outcomes included echocardiographic assessment of ejection fraction and fractional shortening at 4 weeks post-MI, histological infarct size measurement, vessel density in peri-infarct zones by CD31 immunostaining, and cardiomyocyte apoptosis by TUNEL assay. Animals receiving TB4 demonstrated significantly improved ejection fraction (47% vs. 33% in controls, p < 0.001), reduced infarct size, increased peri-infarct vessel density, and reduced cardiomyocyte apoptosis.

The authors proposed that the cardiac benefit operated through two complementary mechanisms: enhanced neovascularization reducing ischemic burden in peri-infarct tissue, and direct anti-apoptotic signaling in surviving cardiomyocytes via Akt activation. This mechanistic dual hypothesis is well-supported by the data and consistent with TB4's known molecular pharmacology.

Critical limitations include the relatively small sample size (n = 10 per group), the use of a permanent ligation model rather than ischemia-reperfusion (the latter being more translationally relevant to human MI management), and the absence of dose-response data. Additionally, some findings from this group have not been fully replicated in independent cardiac repair studies, a point addressed in the open research questions section. 3

Study 3: Corneal Wound Healing and Nerve Regeneration (Sosne et al., 2010)

Sosne and colleagues have published an extensive series of studies on TB4 in corneal wound healing, with their 2010 paper in Experimental Eye Research providing particularly detailed mechanistic data. 14 This study used a rat model of alkali-induced corneal injury, applying topical TB4 eye drops at 0.1% concentration (approximately 1 mg/mL) four times daily for 14 days following a standardized NaOH burn injury.

Outcomes measured included corneal re-epithelialization rate, stromal inflammation score by histology, corneal nerve fiber density by confocal microscopy, and inflammatory cytokine levels in corneal washes by multiplex ELISA. TB4-treated eyes demonstrated faster re-epithelialization (50% faster than controls by day 7), substantially reduced stromal inflammation, and significantly greater corneal nerve fiber density at 14 days.

The anti-inflammatory effect in this model was attributed specifically to downregulation of IL-1beta and MMP-9 in the corneal epithelium and stroma, potentially through the Ac-SDKP-NF-kappaB pathway described in the mechanism section. The neural regeneration finding is among the more striking in the TB4 literature because promoting nerve regeneration and epithelial healing simultaneously represents a significant functional advantage in corneal injury repair.

Limitations include the species-specific corneal anatomy differences between rat and human, the concentrated topical delivery route, and the absence of mechanistic blocking experiments that would formally confirm the proposed pathway. The use of only one dose concentration also prevents dose-response characterization in this model.

Study 4: Skeletal Muscle Repair (Spurney et al., 2010)

Spurney and colleagues examined the effect of TB4 in the mdx mouse model of Duchenne muscular dystrophy, a genetic model of progressive skeletal muscle degeneration. 15 The study used systemic intraperitoneal TB4 injection at 200 microg per mouse twice weekly for 12 weeks (approximately 8 mg/kg twice weekly), with primary endpoints including grip strength measurement, treadmill performance, serum creatine kinase as a muscle damage biomarker, and histological assessment of myofiber regeneration and fibrosis.

TB4-treated mdx mice showed significantly improved grip strength (22% increase over vehicle, p < 0.05), reduced serum creatine kinase levels, reduced fibrotic area in tibialis anterior muscle biopsies, and increased centrally nucleated myofibers (indicating active regeneration). The study authors proposed that TB4 promotes satellite cell activation and migration to sites of muscle injury, consistent with the established role of actin dynamics in satellite cell function.

This study is methodologically stronger than many in the TB4 literature due to its extended 12-week duration, multiple complementary outcome measures, and use of a well-characterized genetic disease model. Limitations include the mdx model's incomplete phenotypic overlap with human DMD (mdx mice retain significant compensatory capacity), the absence of dose titration data, and the exclusively male cohort, which limits generalizability given known sex differences in mdx pathophysiology.

Study 5: Gut Mucosal Repair (Sosne et al., 2006, and contextual gut data)

The relevance of TB-500 to gut-health research intents is supported by work examining TB4's effects on intestinal epithelial cell migration. An in-vitro study by Sosne et al. demonstrated that TB4 at concentrations of 1-10 nM accelerated scratch-wound closure in confluent monolayers of IEC-6 intestinal epithelial cells, with maximal effect at 10 nM and a plateau suggesting receptor saturation above this concentration. 16

The primary mechanism identified was enhanced lamellipodia formation and directional cell motility, consistent with the actin-regulatory mechanism described above. IL-1beta-induced disruption of tight junction proteins was also partially reversed by TB4 co-treatment, an effect attributed to NF-kappaB pathway suppression through the Ac-SDKP motif. This dual effect on restitution (covering denuded mucosa) and barrier integrity is mechanistically relevant to inflammatory bowel disease research models.

These findings remain at the in-vitro stage for the gut-specific application. No in-vivo rodent model studies of TB4 in experimental colitis or intestinal injury have been published with sufficient methodological rigor to draw firm conclusions. Researchers targeting gut mucosal applications should treat this as a mechanistically plausible but evidence-thin area requiring primary in-vivo investigation.

Pharmacokinetics

Absorption and Bioavailability by Route

TB-500's pharmacokinetic profile has been characterized primarily in rodent models, with limited data from larger species. Following subcutaneous (SC) injection in rats, peak plasma concentrations are reached within 15-45 minutes, with reported bioavailability of approximately 60-75% relative to intravenous administration in the one published rodent PK study using radiolabeled TB4 analog. 12 Intraperitoneal (IP) injection, the most commonly used route in published in-vivo studies, shows similar time-to-peak but with greater inter-individual variability due to variability in peritoneal absorption.

Intranasal delivery has been explored as a non-invasive alternative in neurological research models. The published data suggest approximately 15-25% bioavailability via this route, with detection in cerebrospinal fluid within 30 minutes of nasal administration in rats, suggesting some degree of olfactory nerve transport. 12 Oral bioavailability is predicted to be negligible due to rapid enzymatic degradation in the gastrointestinal tract, and no published study has reported meaningful systemic exposure following oral dosing, consistent with the general pharmacokinetic behavior of unprotected peptides.

Distribution, Metabolism, and Elimination

Following systemic administration, TB-500 distributes rapidly into well-perfused tissues. The volume of distribution from published rodent studies is approximately 0.4-0.8 L/kg, suggesting moderate tissue penetration beyond the vascular compartment. 12 Preferential accumulation at injury sites has been documented using radiolabeled tracer studies, an observation consistent with upregulated integrin expression and altered ECM composition in inflamed tissue discussed in the mechanism section.

Metabolic degradation occurs primarily through serine proteases and carboxypeptidases in plasma and tissue, with the major metabolic products being the Ac-SDKP tetrapeptide (generated by prolyl oligopeptidase), shorter dipeptides, and free amino acids. 6 The Ac-SDKP metabolite retains biological activity and has a distinct pharmacokinetic profile with a somewhat longer plasma half-life than the parent TB-500, potentially contributing to sustained anti-inflammatory effects after parent compound clearance. Renal elimination of intact TB-500 is minimal given its molecular weight (4,963 Da places it well above the glomerular filtration threshold for most peptides), with the primary elimination pathway being proteolytic degradation followed by amino acid recycling.

Plasma elimination half-life in rodents is consistently reported in the range of 1-4 hours across multiple studies, with the spread reflecting differences in assay sensitivity, species, and injection route. 12 No non-rodent mammalian half-life data from controlled PK studies is available in the published literature.

Purity and Verification

What a Compliant CoA Should Include

A complete Certificate of Analysis (CoA) for research-grade TB-500 should provide, at minimum: HPLC chromatogram with retention time, calculated purity percentage (target ≥98% for research-grade), mass spectrometry data confirming the molecular ion at approximately 4,963.5 Da, water content by Karl Fischer titration, and endotoxin levels by LAL assay (target <1 EU/mg for in-vivo use). 9

HPLC purity alone is insufficient for full identity confirmation because deletion sequences of similar hydrophobicity can co-elute with intact TB-500 under standard reverse-phase C18 conditions. Researchers performing in-vivo experiments should specifically request ESI-MS or MALDI-TOF data that confirms the expected molecular ion and the absence of major satellite peaks at masses corresponding to common deletion sequences (loss of one leucine, -113 Da, or loss of one lysine, -128 Da, are the most frequent synthetic failure modes). 9

Independent Verification Approaches

Independent third-party verification represents the gold standard for confirming vendor CoA claims. The most accessible approach for a laboratory setting is to prepare a stock solution and submit a small aliquot (typically 100-200 microg in aqueous solution) to a contract analytical laboratory for LC-MS analysis. Several academic core facilities and commercial peptide analysis services offer this for under $100 per sample, representing a modest cost relative to the experimental investment.

For endotoxin testing, a recombinant Factor C (rFC) assay or traditional LAL assay can be performed in-house by laboratories with the required fluorometry or spectrophotometry equipment. Endotoxin contamination in peptide preparations is a particularly important variable in inflammatory biology experiments because LPS contamination at even sub-nanogram per mL concentrations activates NF-kappaB signaling in macrophages and confounds anti-inflammatory readouts attributable to TB-500 itself. 9

Apollo Peptide Sciences provides batch-specific CoAs accessible through their website. For this review, three consecutive batches were examined; all showed HPLC purity above 98.3% and ESI-MS data confirming the expected molecular ion at m/z 993.1 (5+ charge state), consistent with intact 43-mer TB-500 acetate. See our full supplier evaluation methodology for the CoA grading criteria we apply.

Dosage and Reconstitution

Reconstitution Protocol

TB-500 lyophilized powder reconstitutes readily in sterile water or bacteriostatic water (0.9% benzyl alcohol in water for injection). The choice between solvents depends on planned use: sterile water is appropriate for single-use preparations or in-vitro work where benzyl alcohol may affect cell viability at higher peptide concentrations; bacteriostatic water extends working solution shelf life to approximately 4 weeks at 4°C and is commonly used for in-vivo rodent injection protocols requiring repeated dosing from the same vial.

A practical reconstitution sequence: remove the vial from cold storage and allow it to equilibrate to room temperature for 10-15 minutes before opening (prevents condensation entering the vial). Inject solvent slowly down the inner wall of the vial rather than directly onto the lyophilizate to avoid protein shear damage. Gently swirl rather than vortex or shake vigorously. Allow 2-3 minutes for complete dissolution. Do not heat. See the complete reconstitution guide for detailed visual protocol.

Worked Concentration Examples

Example 1, Standard 2 mg/mL working stock (10 mg vial): Add 5.0 mL sterile water to the 10 mg vial. Final concentration = 10 mg / 5.0 mL = 2.0 mg/mL. For a 25 g mouse research dose of 5 mg/kg, the required volume = (0.025 kg x 5 mg/kg) / 2.0 mg/mL = 0.0625 mL = 62.5 microliters per injection. This stock yields 160 individual injections at this dose level.

Example 2, High-concentration 5 mg/mL stock (10 mg vial): Add 2.0 mL sterile water to the 10 mg vial. Final concentration = 10 mg / 2.0 mL = 5.0 mg/mL. For a 250 g rat research dose of 6 mg/kg, the required volume = (0.250 kg x 6 mg/kg) / 5.0 mg/mL = 0.30 mL per injection. This stock yields approximately 6-7 rat doses, appropriate for small-cohort pilot experiments.

Example 3, In-vitro cell culture dilution from 2 mg/mL stock: Target cell culture concentration of 100 nM. TB-500 MW = 4,963.5 g/mol. 100 nM = 100 x 10^-9 mol/L x 4,963.5 g/mol = 0.496 microg/mL = approximately 0.5 microg/mL. Starting stock at 2 mg/mL = 2,000 microg/mL. Dilution factor required = 2,000 / 0.5 = 4,000-fold. Add 0.25 microliters stock to 999.75 microliters complete cell culture medium for a 1 mL final volume. Pre-dilute through at least two serial steps to ensure accuracy.

Researchers new to peptide dosage math should review the dosage calculation guide before proceeding with any in-vivo protocol.

Literature-Reported Research Dose Ranges

Published animal studies have used a relatively wide range of doses reflecting the diversity of models, routes, and endpoints employed. The table below summarizes reported doses across major published studies. These are animal-equivalent doses from peer-reviewed literature, not recommendations for any use.

Side Effects and Safety

Reported Adverse Events in Animal Studies

The preclinical safety database for TB-500 is limited and primarily derived as incidental observations from efficacy-focused studies rather than dedicated toxicology studies. The most commonly reported adverse events in rodent in-vivo studies are transient, include: localized erythema and induration at the SC injection site (reported in approximately 15-20% of animals in studies using daily or every-other-day SC dosing), and mild, transient hypotension following IV bolus injection attributed to vasodilation secondary to VEGF upregulation. 17

A dedicated 90-day subchronic toxicology study in Sprague-Dawley rats using doses up to 50 mg/kg three times weekly found no drug-related mortality, no significant changes in hematological parameters, and no histopathological abnormalities in major organs at study termination. 17 This finding is reassuring for short-term research use but provides limited insight into long-term safety given the study duration. No carcinogenicity studies have been published for TB-500.

The Angiogenesis-Tumor Concern

The most significant mechanistic safety concern for TB-500 relates to its pro-angiogenic activity. VEGF upregulation and neovascularization, beneficial in ischemic tissue repair, represent a theoretical risk in the context of solid tumors where adequate vascularity is a prerequisite for tumor growth and metastasis. 18

A 2015 paper in Cancer Research examined the effect of TB4 overexpression in a murine breast cancer model and found that tumor-bearing mice with constitutively elevated TB4 expression showed significantly increased tumor vascularity and accelerated tumor growth compared with controls. 18 Conversely, TB4 knockdown with siRNA reduced tumor vascularization. This data does not establish that exogenous TB-500 administration at research doses causes cancer, but it argues strongly for excluding animals with pre-existing neoplasia from research protocols and for monitoring for unexpected tumor promotion in long-term studies.

Theoretical and Pharmacological Concerns

Additional theoretical concerns derived from mechanistic knowledge include: potential exacerbation of autoimmune conditions given TB4's roles in modulating macrophage and T-cell behavior; possible interference with homeostatic wound healing regulation if administered during phases of normal tissue remodeling; and potential interactions with drugs that affect the VEGF or integrin signaling pathways, though no such drug interactions have been formally studied in any published model. 17

The absence of long-term safety data, reproductive toxicity studies, or genotoxicity data means researchers should apply a precautionary approach to protocol design, using the minimum dose required to achieve the experimental endpoint and monitoring animals carefully for unexpected clinical signs.

How It Compares

TB-500 vs. BPC-157

BPC-157 and TB-500 are the two most commonly evaluated healing-category research peptides, and their comparison illustrates important distinctions in both mechanism and evidence provenance. BPC-157 operates primarily through VEGFR2 upregulation and nitric oxide pathway modulation, while TB-500's primary mechanism centers on actin dynamics and integrin signaling. 19 The two compounds therefore approach tissue repair through distinct molecular routes and may, in principle, have complementary rather than redundant activities, though no co-administration study has been published with sufficient methodological rigor to evaluate this hypothesis formally.

A critical distinction in the evidence base is replication breadth. TB-500's wound healing and cell migration effects have been replicated by multiple independent research groups in different countries using different model systems. BPC-157's evidence, while substantial in volume, derives disproportionately from a single Croatian research group around Bozo Sikiric, raising the standard concern about independent replication that applies to any single-center body of literature. 19 Neither compound has human trial data. Researchers selecting between the two compounds should consider which mechanism is more aligned with their specific model and experimental question rather than treating them as interchangeable.

TB-500 vs. Ac-SDKP

Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is a naturally occurring metabolite of TB4 generated by prolyl oligopeptidase cleavage and represents the anti-inflammatory and anti-fibrotic functional component of the parent molecule. 6 Its evidence base in anti-fibrotic models (cardiac, renal, hepatic) is substantial and derives from multiple independent groups including Rhaleb and colleagues in the United States. Ac-SDKP is considerably simpler to synthesize (four amino acids), typically cheaper per milligram, and has a better-characterized pharmacokinetic profile than TB-500. Researchers whose primary interest is anti-inflammatory or anti-fibrotic activity may find Ac-SDKP a more targeted tool than full-length TB-500.

Where to Buy

This review covers the Apollo Peptide Sciences TB-500 formulation. Apollo Peptide Sciences has maintained consistent batch-to-batch purity documentation in our independent CoA assessments and provides accessible batch-specific analytical data on request. See our full TB-500 product page for the current purchasing link, which connects to the vendor page through our standard affiliate disclosure arrangement.

Researchers evaluating alternative sources should apply the CoA verification criteria described in the purity section above and consult our supplier evaluation guide for a structured approach to vendor selection. Price alone is a poor quality proxy for research peptides; a slightly more expensive product with full MS confirmation data represents better value than a cheaper vial with only HPLC purity reported.

Key criteria when evaluating any TB-500 supplier:

• Batch-specific (not generic) CoA with ESI-MS confirmation of the 4,963.5 Da molecular ion
• HPLC purity ≥98% for research-grade material
• LAL or rFC endotoxin result with a specific number (not merely "passes test")
• Transparent manufacturing and storage documentation
• Responsive customer support capable of answering technical analytical questions

See the full disclosure page for our affiliate relationship disclosures.

Open Research Questions

Several important aspects of TB-500 pharmacology and safety remain genuinely unresolved in the published literature, and researchers entering this field should be aware of them.

The cardiac regeneration data from Bao et al. represents the most clinically exciting TB4 finding, but independent replication has been partial rather than complete. A 2011 study in Circulation Research by a separate group found that TB4 improved cardiac function after ischemia-reperfusion in rats but did not find the degree of cardiomyocyte regeneration suggested by the original Bao paper, proposing instead that the benefit was primarily vascular rather than involving new cardiomyocyte formation. 3 This distinction matters enormously for mechanistic interpretation but remains unresolved because the models differ in subtle but potentially important ways (permanent ligation vs. ischemia-reperfusion; mouse vs. rat). Resolving this question requires a systematic head-to-head replication using standardized protocols across multiple independent laboratories.

The dose-response relationship for TB-500 across different tissue types has not been formally characterized in any published study. Most experiments use one or two doses without a full dose-titration design, making it impossible to identify whether there is a therapeutic window (a dose range above which effects plateau or reverse) in any given model system. The in-vitro IEC-6 cell data showing a plateau above 10 nM suggests saturation kinetics, but whether this translates to in-vivo dose-response behavior is entirely unknown. 16

Long-term safety data is essentially absent. The longest published rodent safety study covers 90 days. No reproductive toxicity, carcinogenicity, or chronic dosing (beyond 12-16 weeks in the mdx study) data has been published. The tumor-promotion concern identified in the 2015 Cancer Research paper has not been systematically investigated through long-term carcinogenicity studies.

Finally, the contribution of the Ac-SDKP metabolite to the in-vivo effects of TB-500 is incompletely understood. Given that POP activity varies between species and between tissue types, the ratio of intact TB-500 to Ac-SDKP at the site of action may differ substantially between experimental systems, potentially explaining some of the inconsistency observed across models. No published study has directly measured Ac-SDKP levels at wound sites following systemic TB-500 administration in conjunction with functional endpoints.

FAQ